Cardiol Therapeutics Inc. cash flow statement

In fiscal 2021, Cardiol Therapeutics Inc.'s operations generated −$18.8m of cash; it spent $10,308 on capital projects, leaving free cash flow of −$18.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cardiol Therapeutics Inc.: cash flow statement, annual
Fiscal year	2021Dec 2021
Cash from operations	−19
Depreciation and amortisation	0
Stock-based pay	7
Capital spending	0
Free cash flow	−19
Free cash flow after stock pay	−26

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Cardiol Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cardiol Therapeutics Inc.